Seat assembly

Information

  • Patent Grant
  • 11173818
  • Patent Number
    11,173,818
  • Date Filed
    Wednesday, May 13, 2020
    4 years ago
  • Date Issued
    Tuesday, November 16, 2021
    2 years ago
Abstract
A seat assembly may include a seat including a seat base and a seat back, a sensor, a vent unit disposed at least partially within the seat back, and/or an electronic control unit (ECU) connected with the sensor and the vent unit. The ECU may be configured to determine, via the sensor, if a user of the seat exhibits symptoms of fatigue. The ECU may be configured to operate the vent unit in a first mode and a second mode. When the vent unit is in the first mode, the vent unit may provide cool air to said user of the seat. When the vent unit is in the second mode, the vent unit may provide warmer and/or less air to said user of the seat. The ECU may automatically switch the vent unit between first and second modes to reduce symptoms of fatigue.
Description
TECHNICAL FIELD

The present disclosure generally relates to seat assemblies including seat assemblies that may be used in connection with automatically sensing and reducing fatigue.


BACKGROUND

This background description is set forth below for the purpose of providing context only. Therefore, any aspect of this background description, to the extent that it does not otherwise qualify as prior art, is neither expressly nor impliedly admitted as prior art against the instant disclosure.


Some seat assemblies may not when a user is experiencing fatigue. For example, some set assemblies may not be configured to reduce fatigue of a user by supplying cool air proximate a neck of a user.


There is a desire for solutions/options that minimize or eliminate one or more challenges or shortcomings of seat assemblies. The foregoing discussion is intended only to illustrate examples of the present field and is not a disavowal of scope.


SUMMARY

In embodiments, a seat assembly may include a seat including a seat base and a seat back, a sensor, a vent unit disposed at least partially within the seat back, and/or an electronic control unit (ECU) connected with the sensor and the vent unit. The ECU may be configured to determine, via the sensor, if a user of the seat exhibits symptoms of fatigue. The ECU may be configured to operate the vent unit in a first mode and a second mode. When the vent unit is in the first mode, the vent unit may provide cool air to said user of the seat. When the vent unit is in the second mode, the vent unit may provide a lesser amount of cool air and/or air at a higher temperature than the cool air to said user of the seat. The ECU may be configured to automatically switch the vent unit between the first mode and the second mode to reduce symptoms of fatigue of said user.


With embodiments, a seat assembly may include a seat including a seat base, a seat back, and a headrest, a bladder assembly disposed at least partially in the seat, a biomedical sensor configured to sense biomedical information of a user of the seat, an actuator assembly configured to control a position of the seat base and/or the seat back, a vent unit disposed at least partially within the seat back and including a portion disposed proximate the headrest, a PEMF coil assembly disposed at least partially in the seat back, and/or an ECU configured to control the actuator assembly, the bladder assembly, the vent unit, and the PEMF coil assembly. The biomedical sensor may be at least partially integrated with the bladder assembly. The ECU may be configured to determine, via the biomedical sensor, if a user of the seat exhibits symptoms of fatigue. The ECU may be configured to automatically operate the vent unit in a first mode and a second mode in an alternating configuration to reduce the fatigue symptoms of said user. When the vent unit is in the first mode, the vent unit may provide cool air to an area proximate a neck of said user. When the vent unit is in the second mode, the vent unit may provide a lesser amount of cool air and/or provides air at a higher temperature than the cool air. The ECU may be configured to automatically activate the actuator assembly, the bladder assembly, and/or the PEMF coil assembly when the vent unit is in the first mode to reduce the fatigue symptoms of said user.


In embodiments, a method of operating a seat assembly may include sensing, via the biometric sensor, if a user of the seat exhibits symptoms of fatigue, and/or automatically operating the vent unit in a first mode for a first duration and in a second mode for a second duration to reduce the symptoms of fatigue of said user. When the vent unit is in the first mode, the vent unit may supply cool air to said user. When the vent unit is in the second mode, the vent unit may provide a lesser amount of cool air and/or provides air at a higher temperature than the cool air.


The foregoing and other potential aspects, features, details, utilities, and/or advantages of examples/embodiments of the present disclosure will be apparent from reading the following description, and from reviewing the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

While the claims are not limited to a specific illustration, an appreciation of various aspects may be gained through a discussion of various examples. The drawings are not necessarily to scale, and certain features may be exaggerated or hidden to better illustrate and explain an innovative aspect of an example. Further, the exemplary illustrations described herein are not exhaustive or otherwise limiting, and are not restricted to the precise form and configuration shown in the drawings or disclosed in the following detailed description. Exemplary illustrations are described in detail by referring to the drawings as follows:



FIG. 1 is a side view generally illustrating an embodiment of a seat assembly according to teachings of the present disclosure.



FIG. 2 is a front view generally illustrating portions of an embodiment of a seat assembly according to teachings of the present disclosure.



FIG. 3 is a schematic via generally illustrating portions of an embodiment of a seat assembly according to teachings of the present disclosure.



FIG. 4 is a graph generally illustrating an embodiment of operating a seat assembly according to teachings of the present disclosure.



FIG. 5 is a flowchart generally illustrating an embodiment of a method of operating a seat assembly according to teachings of the present disclosure.





DETAILED DESCRIPTION

Reference will now be made in detail to embodiments of the present disclosure, examples of which are described herein and illustrated in the accompanying drawings. While the present disclosure will be described in conjunction with embodiments and/or examples, it will be understood that they do not limit the present disclosure to these embodiments and/or examples. On the contrary, the present disclosure covers alternatives, modifications, and equivalents.


In embodiments, such as generally illustrated in FIGS. 1 and 2, a seat assembly 20 may include a seat 30, an electronic control unit (ECU) 50, a sensor 70, an actuator assembly 78 having a first actuator 80 and/or a second actuator 82, a first bladder assembly 90, a second bladder assembly 100, a vent unit 120, and/or a pulsed electromagnetic field (PEW′) coil assembly 130. The ECU 50 may be connected with the seat 30, the sensor 70, the actuator assembly 78, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130.


With embodiments, the ECU 50 may be configured to determine if a user (e.g., an occupant of the seat 30) exhibits signs/symptoms of fatigue, such as via the sensor 70 and/or a user interface 72. Symptoms of fatigue may, for example and without limitation, include large movements/fidgets by the user relative to the seat 30 that may be associated with long occupancy periods (e.g., vehicle trips of about 30 minutes or more). The ECU 50 may be configured to activate/control the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130, such as to reduce discomfort and/or reduce symptoms of fatigue of a user.


With embodiments, such as generally illustrated in FIGS. 1 and 2, a seat assembly 20 may include one or more seats 30. The seat 30 may include a seat base 32, a seat back 34, and/or a headrest 36. The seat 30 may be selectively connected (e.g., electrically and/or mechanically) to a track assembly 40. The ECU 50 may be configured to at least partially control operation of the seat 30. The ECU 50 may be electrically connected to the seat 30, such as via the track assembly 40. The seat 30 may be connected with the track assembly 40 via a support member 38. The support member 38 may be selectively connected with the track assembly 40. For example and without limitation, the support member 38 may be configured to be inserted vertically and/or horizontally into the track assembly 40. The support member 38 may be configured to be removed vertically and/or horizontally from the track assembly 40. The support member 38 may be configured to move along the track assembly 40 (e.g., in an X-direction and/or a Y-direction).


In embodiments, such as generally illustrated in FIGS. 1 and 2, a track assembly 40 may be disposed on and/or fixed to a mounting surface 42 (e.g., a vehicle floor). The track assembly 40 may be configured to receive the seat 30 substantially in an X-direction (e.g., a longitudinal direction) and/or a Z-direction (e.g., a vertical direction). The seat 30 and/or the support member 38 may be configured to be selectively inserted into and/or selectively removed from the track assembly 40 in one or more of a variety of locations along the track assembly 40 (e.g., one location, two locations, three or more locations, etc.). The track assembly 40 may, for example and without limitation, include one or more of variety of shapes, sizes, and/or configurations. The track assembly 40 may extend in an X-direction and/or a Y-direction (e.g., a transverse direction) such that the seat 30 may move in the X-direction and/or the Y-direction along the track assembly 40. With embodiments, a seat 30 may be connected to a mounting surface 42 independently of a track assembly 40 and/or a support member 38 (e.g., a seat assembly 20 may not include a track assembly 40).


With embodiments, such as generally illustrated in FIGS. 1, 2, and 3, the seat assembly 20 may include one or more sensors 70. A sensor 70 may be configured to sense (e.g., measure, detect, obtain, monitor, etc.) biomedical and/or biometric information of the user occupying the seat 30, and the sensor 70 may be referred to herein as a biomedical sensor 70, but is not limited to a biomedical sensor. The sensor 70 may be configured to identify a user, and/or sense heart rate, breathing rate, blood pressure, fidgets/movements, and/or other information related to the user. For example and without limitation, the sensor 70 may include one or more cameras/visual devices, heart rate sensors, breathing rate sensors, blood pressure sensors, and/or fidget/movement sensors (e.g., force/pressure sensors), among others. The sensor 70 may be disposed proximate the seat 30, such as in a vehicle cabin, in the seat base 32, and/or the seat back 34. The sensor 70 may be disposed substantially proximate a seating surface 30A of the seat 30, such as to increase the accuracy of sensed biomedical information. The sensor 70 may be configured to sense and/or obtain information associated with or indicating fatigue and/or discomfort of a user of/occupying the seat 30. Fatigue symptoms may, for example and without limitation, include increased or more significant movement/fidgeting, reduced or irregular heart rate, reduced or irregular heart rate variability, and/or reduced or irregular blood pressure (e.g., relative to baseline values/information that may be provided to and/or determined by the ECU 50), among others.


With embodiments, a sensor 70 may, for example and without limitation, include portions of and/or be integrated at least partially with the first bladder assembly 90 and/or the second bladder assembly 10. In some circumstances, the sensor 70 may include one or more pressure sensors connected to and/or integrated with the first bladder assembly 90 and/or the second bladder assembly 100. Changes in pressure in the bladder assemblies 90, 100 (and/or bladders thereof) may be sensed via the sensor 70 and may indicate that a user is fidgeting and/or is experiencing discomfort. The amount of a pressure change may correspond to the magnitude of the movement.


In embodiments, the ECU 50 may be electrically connected (e.g., via wired and/or wireless connection) with the sensor 70, such as to determine if the user exhibits signs of fatigue/discomfort. The ECU 50 may be configured to activate one or more seat functions, such as the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130, to reduce sensed fatigue symptoms/discomfort of the user. Additionally or alternatively, the user may manually activate the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130, such as via a user interface 72 (e.g., when the user desires to reduce symptoms of fatigue and/or discomfort). The user interface 72 may be configured to receive one or more of a variety of inputs (e.g., physical touch, audio, motion, etc.) from the user. For example and without limitation, at least a portion of the user interface 72 may be disposed substantially proximate the seat 30 such that the user may interact with the user interface 72 via physical touch.


In embodiments, the ECU 50 may be configured to monitor automatic and/or manual use of seat functions, such as the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130. The ECU 50 may, for example, monitor use of the seat assembly 20 to predict (via machine learning) when the user is likely to experience fatigue/discomfort during a trip. For example and without limitation, if a user has a history of manually activating one of more seat functions and/or exhibiting fatigue symptoms after a certain amount of time into trips, the ECU 50 may automatically activate one or more seat functions before that certain time. The ECU 50 may proactively activate functions of the seat assembly 20 to prevent and/or minimize user fatigue symptoms/discomfort.


With embodiments, such as generally illustrated in FIGS. 1, 2, and 3, an actuator assembly 78 of a seat assembly 20 may include a first actuator 80 that may be connected with the seat base 32 and/or may include a second actuator 82 that may be connected with the seat back 34. The first actuator 80 and/or the second actuator 82 may be connected to and/or disposed at least partially in the seat 30 and/or the support member 38. The first actuator 80 may be configured to actuate (e.g., rotate, shift, tilt, etc.) the seat base 32. The second actuator 82 may be configured to actuate the seat back 34. For example and without limitation, the first actuator 80 may be configured to rotate the seat base 32 in a first direction (e.g., clockwise in FIG. 1) and/or a second direction (e.g., counterclockwise in FIG. 1), such as about 90 degrees or more or less. The second actuator 82 may be configured to rotate the seat back 34 in a first direction (e.g., clockwise in FIG. 1) and/or a second direction (e.g., counterclockwise in FIG. 1), such as about 180 degrees, or more or less. The ECU 50 may be configured to control operation of the first actuator 80 and/or the second actuator 82. For example and without limitation, the first actuator 80 and/or the second actuator 82 may be electrically connected (e.g., via wired and/or wireless connection) with the ECU 50. The first actuator 80 and/or the second actuator 82 may be manually controlled by the user, such as via the user interface 72, and/or may be automatically controlled by the ECU 50 (e.g., for automatically preventing/reducing discomfort and/or fatigue symptoms).


In embodiments, such as generally illustrated in FIGS. 1, 2, and 3, a first bladder assembly 90 may include one or more bladders 92N (e.g., fluid bladders). For example and without limitation, the first bladder assembly 90 may include a first bladder 921, a second bladder 922, a third bladder 923, a fourth bladder 924, a fifth bladder 925, and/or a sixth bladder 926. The first bladder assembly 90 may be disposed at least partially and/or substantially in the seat back 34. The first bladder 921, the third bladder 923, and/or the fifth bladder 925 may be disposed substantially proximate a first side 34A of the seat back 34 (e.g., the left side in FIG. 2) and/or a first bolster 34C of the seat back 34. The second bladder 922, the fourth bladder 924, and/or the sixth bladder 926 may be disposed substantially proximate a second side 34B of the seat back 34 (e.g., the right side in FIG. 2) and/or a second bolster 34D of the seat back 34. The first side 34A of the seat back 34 may be substantially opposite the second side 34B of the seat back 34. The first bladder 921 and/or the second bladder 922 may be disposed in the seat back 34 such that the first bladder 921 and/or the second bladder 922 may be generally proximate a shoulder area of the user. The third bladder 923 and/or the fourth bladder 924 may be disposed in the seat back 34 such that the third bladder 923 and/or the fourth bladder 924 may be generally proximate a thoracic area of the user (e.g., below the first and second bladders 921, 922). The fifth bladder 925 and/or the sixth bladder 926 may be disposed in the seat back 34 such that the fifth bladder 925 and/or the sixth bladder 926 may be generally proximate a lumbar area of the user (e.g., below the third and fourth bladders 923, 924).


With embodiments, the ECU 50 may be configured control operation (e.g., inflation/deflation) of the bladders 92N. For example and without limitation, the ECU 50 may be may be electrically connected (e.g., via wired and/or wireless connection) with the first bladder assembly 90 and/or a fluid source 74 that may be in fluid communication with the first bladder assembly 90, such as via one or more fluid conduits 76 (e.g., tubes, hoses, ducts, etc.). The fluid source 74 may, for example and without limitation, include a fluid pump, a fan, fluid reservoir, and/or one or more control valves, among other components, that may be configured to selectively provide fluid (e.g., air) to and/or remove fluid from the first bladder assembly 90 and/or the second bladder assembly 100. The ECU 50 may control the fluid source 74 to control the bladder assemblies 90, 100.


In embodiments, the ECU 50 may be configured to independently control operation of the first bladder 921, the second bladder 922, the third bladder 923, the fourth bladder 924, the fifth bladder 925, and/or the sixth bladder 926. The ECU 50 may inflate and/or deflate the first bladder assembly 90 such as to provide a massaging effect to the back of a user. The ECU 50 may be configured to inflate the bladders 92N to one or more of a variety of pressures (e.g., that may be associated with a variety of massage pressure intensities). For example and without limitation, the ECU 50 may inflate the bladders 92N to a first level of intensity and/or a second level of intensity. The first level of intensity of the bladders 92N may correspond with a light massaging. The second level of intensity of the bladders 92N may correspond to a pressure to warm up tissues in the back of the user. The second level of intensity of the bladders 92N may apply a greater pressure to the back of a user than the first level of intensity of the bladders 92N.


In embodiments, the ECU 50 may be configured to automatically activate the first bladder assembly 90 upon determining that the user exhibits symptoms of fatigue/discomfort. For example and without limitation, the ECU 50 may determine that the user exhibits signs of fatigue/discomfort, such as via the sensor 70, and/or in response, the ECU 50 may automatically activate the first bladder 921, the second bladder 922, the fifth bladder 925, and/or the sixth bladder 926 at the first level and/or the second level. Additionally or alternatively, the user may manually activate the bladders 92N, such as via the user interface 72 that may be connected with the ECU 50 and/or the first bladder assembly 90. With some embodiments, the user may manually control inflation and/or deflation of respective bladders 92N independently, such as to the first level and/or the second level via the user interface 72.


With embodiments, such as generally illustrated in FIGS. 1, 2, and 3, the second bladder assembly 100 may include one or more bladders. For example and without limitation, the second bladder assembly 100 may include one or more second assembly bladders 102. The second assembly bladders 102 may, for example, be disposed substantially in the seat base 32, such as at or about a bight line and/or at or about bolsters 32A, 32B of the seat base. The ECU 50 may control the second bladder assembly 100, such as via an electrical connection, and/or via a fluid source 74 that may be in fluid communication with the bladder 102. The ECU 50 may be configured to inflate and/or deflate the bladder 102, such as to adjust a position of the user while occupying the seat 30. Inflating and deflating the bladder 102 (e.g., adjusting the seating position of the user) may reduce fatigue/discomfort and/or fidgets exhibited by the user. The ECU 50 may inflate the bladder 102 to one or more of a variety of different pressures. For example and without limitation, the ECU 50 may (e.g., automatically) inflate the bladder 102 to a low pressure, a medium pressure, and/or a high pressure, such as according to a degree of fatigue/discomfort sensed via the sensor 70. The ECU 50 may inflate the bladder 102 to the low pressure to reduce a lesser degree of fatigue/discomfort, and/or the ECU 50 may inflate the bladder 102 to the high pressure to reduce a greater degree of fatigue/discomfort.


In embodiments, the ECU 50 may be configured to automatically activate the second bladder assembly 100 upon determining (e.g., via the sensor 70) that the user exhibits signs/symptoms of fatigue/discomfort. The ECU 50 may automatically inflate the second assembly bladder 102 to an appropriate pressure level (e.g., low pressure, medium pressure, and/or high pressure) to minimize one or more of a variety of fatigue levels of the user. Additionally or alternatively, the user may manually activate the bladder 102 (e.g. at a variety of pressures), such as via the user interface 72 that may be connected with the ECU 50 and/or the second bladder assembly 100.


With embodiments, such as generally illustrated in FIGS. 1, 2, and 3, a seat assembly 20 may include a vent unit 120. A vent unit 120 may, for example and without limitation, include an air conditioner, a fan, a pump, a heater, and/or one or more air ducts. The vent unit 120 may be configured to provide air substantially proximate an upper portion of the seat back 34 and/or substantially proximate the headrest 36, such as to provide air to a head, a neck, a shoulder area, and/or a torso of a user. The vent unit 120 may, for example and without limitation, be configured to move air from an area inside of the seat back 34 (and/or behind/below the seat back 34) to an area proximate a seating surface 30A of the seat back 34 (e.g., substantially proximate a head, neck, shoulders, and/or torso of the user). The vent unit 120 may be electrically connected (e.g., via wired and/or wireless connection) with the ECU 50, and/or the ECU 50 may be configured to control the vent unit 120. The ECU 50 may be configured to control the temperature of the air provided by the vent unit 120. The vent unit 120 may be configured to provide air at a plurality of temperatures. For example and without limitation, the vent unit 120 may be configured provide cool air (e.g., cooler than an ambient temperature) that may have a cool air temperature of about 15 degrees Celsius or less, and/or a cool air temperature about 7 degrees Celsius or more below an ambient temperature. A vent unit 120 may be disposed partially and/or substantially in the seat 30, such as in the seat back 34.


In embodiments, a seat assembly 20 may include one or more temperatures sensors, such as a first temperature sensor 122 and/or a second temperature sensor 124, that may be connected (e.g., via wired and/or wireless connection) to the ECU 50. The first temperature sensor 122 may be configured as an ambient temperature sensor and/or may be configured to obtain information relating to one or more ambient temperatures. The ambient temperature may include an exterior temperature (e.g., outside a vehicle) and/or an interior temperature (e.g., a vehicle interior/cabin temperature). The second temperature sensor 124 may be disposed proximate an outlet 120A of and/or at least partially within the vent unit 120. The ECU 50 may monitor the temperature of the air provided by the vent unit 120 via the second temperature sensor 124. For example and without limitation, the ECU 50 may utilize the second temperature sensor 124 to verify that the temperature of the air provided to the user is within a threshold range of a temperature that may be selected by the user (via the user interface 72) and/or the ECU 50.


With embodiments, the ECU 50 may be configured to control the vent unit 120 to provide cool air proximate an upper portion of the body of the user, such as to the ears, the neck, the shoulders, and/or the torso of the user. The ECU 50 may, for example and without limitation, provide cool air to the user to trigger a diving reflex of the user. Triggering a diving reflex involve lowering the temperature proximate the ears, head, neck, shoulders, and/or torso of the user, and may result in one or more physiological changes in the user, such as changes in heart rate, blood pressure, and/or breathing rate/pattern, among others. One or more of such physiological changes may generally tend to counter and/or reduce symptoms of fatigue, at least temporarily.


In embodiments, the ECU 50 may be configured to automatically activate the vent unit 120 upon sensing (e.g., via the sensor 70) that the user exhibits symptoms of fatigue/discomfort. Activating the vent unit 120 may include operating the vent unit 120 in a first mode and/or a second mode. When the ECU 50 operates the vent unit 120 in the first mode, the vent unit 120 may provide cool air to an upper portion of the user. When the ECU 50 operates the vent unit 120 in the second mode, the vent unit 120 may provide air that is warmer than the cool air provided in the first mode (e.g., may provide air at or about an ambient temperature) and/or may not provide a substantial amount of air to the user. The ECU 50 may operate the vent unit 120 in the first mode for a first duration, and/or may operate the vent unit 120 in the second mode for a second duration. For example and without limitation, the first duration may be about 4 minutes or more or less, and/or the second duration may be about 6 minutes or more or less. The ECU 50 may be configured to cycle the vent unit 120 between the first mode and/or the second mode for the first duration and/or the second duration, respectively, for a number of cycles (e.g., repeatedly). Switching from the first mode to the second mode may allow the user and/or air proximate the user to warm up so that when the vent unit 120 switches back to the first mode, the cool air is materially cooler than the user and/or the air proximate the user, which may facilitate triggering the diving reflex of the user again and/or may maximize fatigue symptom reduction via the vent unit 120. If the vent unit 120 is operated in the first mode for an extended period of time, the user may become accustomed to the cool air and/or the effects of triggering the diving reflex may taper off.


With embodiments, the ECU 50 may (e.g., automatically) cycle the vent unit 120 between the first mode and/or the second mode until the sensed biomedical information indicates that the user no longer exhibits or exhibits fewer/less severe symptoms of fatigue. Additionally or alternatively, the ECU 50 may prompt the user for input, such as via the user interface 72, to determine whether to maintain operation (e.g., cyclic operation) of the vent unit 120 or whether to deactivate the vent unit 120. The user may manually activate the vent unit 120 at one or more of a variety of temperatures and/or may override control of the vent unit 120 by the ECU 50 (at least temporarily), such as via the user interface 72, which may be connected with the ECU 50 and the vent unit 120.


In embodiments, such as generally illustrated in FIGS. 1, 2, and 3, a seat assembly 20 may include a PEMF coil assembly 130. The PEMF coil assembly 130 may include one or more PEMF coils 132N. For example and without limitation, the PEMF coil assembly 130 may include a first coil 1321, a second coil 1322, a third coil 1323, a fourth coil 1324, a fifth coil 1325, and/or a sixth coil 1326. The coils 132N may be disposed in the seat back 34. The coils 132N may be disposed in one or more locations within the seat back 34. For example and without limitation, such as generally shown in FIG. 1, the coils 132N may be disposed substantially proximate the bladders 92N of the first bladder assembly 90. With embodiments, such as generally illustrated in FIG. 2, the coils 132N may be disposed at least partially within the bladders 92N of the first bladder assembly 90. For example and without limitation, the first coil 1321 may be disposed at least partially in the first bladder 921, the second coil 1322 may be disposed at least partially in the second bladder 922, the third coil 1323 may be disposed at least partially in the third bladder 923, the fourth coil 1324 may be disposed at least partially in the fourth bladder 924, the fifth coil 1325 may be disposed at least partially in the fifth bladder 925, and/or the sixth coil 1326 may be disposed at least partially in the sixth bladder 926. The PEMF coil assembly 130 may be electrically connected (e.g., via wired and/or wireless connection) with the ECU 50 such that the ECU 50 may activate and/or deactivate the coils 132N of the PEMF coil assembly 130 (e.g., independently).


With embodiments, the ECU 50 may activate one or more coils 132N to reduce fatigue symptoms and/or discomfort, such as fatigue symptoms and/or discomfort that may be associated with osteo-articular pain and/or inflammation. The ECU 50 may independently control operation of the coils 132N to apply PEMF therapy to specific areas of the user. For example and without limitation, the ECU 50 may operate the first coil 1321 and/or the second coil 1322 to provide PEMF therapy substantially proximate a neck/shoulder area of the user. The ECU 50 may operate the third coil 1323 and/or the fourth coil 1324 to provide PEMF therapy substantially proximate a thoracic area of the user. The ECU 50 may operate the fifth coil 1325 and/or the sixth coil 1326 to provide PEMF therapy substantially proximate a lumbar area of the user.


In embodiments, the ECU 50 may be configured to automatically activate the PEMF coil assembly 130 upon sensing that the user is experiencing fatigue symptoms and/or discomfort (e.g., via the sensor 70). Additionally or alternatively, the user may manually activate the coils 132N of the PEMF coil assembly 130, such as via the user interface 72, which may be connected with the ECU 50 and/or the PEMF coil assembly 130. The user may, for example, operate the coils 132N individually to address targeted areas of inflammation and/or osteo-articular pain.


In embodiments, the ECU 50 may determine if the user of the seat 30 is a driver/pilot of a vehicle (e.g., if the seat 30 is disposed in a vehicle, whether the seat 30 is a driver seat), such as according to user input via the user interface 72, and/or whether the user is experiencing fatigue symptoms and/or discomfort. If the ECU 50 determines that user is the driver, the ECU 50 may be configured to activate the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130 to reduce fatigue symptoms and/or discomfort.


With embodiments, the ECU 50 may be configured to determine if the seat 30 is not occupied by a driver (e.g., is not a driver seat) and/or the ECU 50 may be configured to operate functions of a seat 30 differently if the user associated with the seat is not a driver. For example and without limitation, the ECU 50 may suggest activating one or more seat functions to the user, and may suggest not triggering the vent unit 120 to non-driving users if such users are trying to rest/sleep. In some circumstances, the ECU 50 may be configured not to activate the first actuator 80 and/or the second actuator 82 if doing so would interfere with the driving ability of the driver. Additionally and alternatively, if the seat base 32 and/or the seat back 34 are not able to be actuated (e.g., if actuating the seat base 32 and/or the seat back 34 may cause contact with another seat, cargo, and/or other user), the ECU 50 may activate the second bladder assembly 100 to reposition the user as an alternative to repositioning the user via the first actuator 80 and/or the second actuator 82.


With embodiments, such as generally illustrated in FIG. 6, a method 170 of operating a seat assembly 20 may include providing a seat 30, an ECU 50, a sensor 70, an actuator assembly 78, a first bladder assembly 90, a second bladder assembly 100, a vent unit 120, and/or a PEMF coil assembly 130 (step 172). The ECU 50 may be connected to and/or configured to control the sensor 70, the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130. The method 170 may include sensing information (e.g., biomedical information, fatigue symptoms, etc.) of the user occupying the seat 30, via the sensor 70, such as to determine if the user exhibits signs/symptoms of fatigue and/or discomfort (step 174). If the user is in a state of fatigue (e.g., as determined by the ECU 50 and/or the sensor 70), the method 170 may include selectively activating one or more seat functions, such as the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130 to reduce fatigue symptoms exhibited by the user (see, e.g., FIGS. 4 and 5).


With embodiments, the method 170 may include activating the vent unit 120, such as to reduce fatigue symptoms of the user (step 176). In embodiments, such as generally illustrated in FIG. 4, activating the vent unit 120 may include operating the vent unit 120 in the first mode for a first duration, such as about 4 minutes or more or less, and/or the second mode for a second duration, such as about 6 minutes or more or less (see, e.g., plot 152). Activating the vent unit 120 may include moving cool air to an area substantially proximate a neck/shoulder area of a user (e.g., which may trigger a diving reflex).


With embodiments, the method 170 may include actuating (e.g., automatically) the seat base 32 via the first actuator 80, and/or actuating the seat back 34 via the second actuator 82 (step 178), such as while the ECU 50 operates the vent unit 120 in the first mode. Activating the first actuator 80 may include rotating the seat base 32 from a first seat base position to a second seat base position in a first direction (e.g., upwards). The first seat base position and the second seat base position may be about 1 degree, or more or less, apart (e.g., angle β as shown in FIG. 1). The first actuator 80 may move the seat base 32 from the first seat base position to the second seat base position over a first duration, which may, for example and without limitation, be about seven seconds or more or less (see, e.g., first actuator plot 160 in FIG. 4). The ECU 50 may maintain the seat base 32 in the second seat base position for a second duration, which may, for example and without limitation, be about five seconds, or more or less. After the second duration, the ECU 50 control the first actuator 80 to rotate the seat base 32 from the second seat base position back to the first seat base position (e.g., in the second direction about 1 degree) over a third duration, which may, for example and without limitation, be about seven seconds (e.g., the third duration may be substantially the same as the first duration).


In embodiments, activating the second actuator 82 may include rotating the seat back 34 from a first seat back position to a second seat back position in a first direction (e.g., backwards), such as about 1.5 degrees or more or less (e.g., angle β in FIG. 1). The second actuator 82 may move the seat base 32 from the first seat back position to the second seat back position over a first duration, which may, for example and without limitation, be about seven seconds or more or less (see, e.g., second actuator plot 162 in FIG. 4). The ECU 50 may maintain the seat back 34 in the second seat back position for a second duration, which may, for example and without limitation, be about five seconds, or more or less. After the second duration, the ECU 50 control the second actuator 82 to rotate the seat back 34 from the second seat back position back to the first seat back position (e.g., in the second direction about 1 degree) over a third duration, which may, for example and without limitation, be about seven seconds (e.g., the third duration may be substantially the same as the first duration).


In some circumstances, the ECU 50 may move the seat base 32 and the seat back 34 from respective first positions to respective second positions at substantially the same time over substantially the same duration (e.g., a first duration), maintain second positions of the seat base 32 and the seat back 34 for the same duration (e.g., a second duration), and/or return the seat base 32 and the seat back 34 to respective first positions over the same duration (e.g., a third duration). In other circumstances, the seat base 32 and the seat back 34 may be operated at different times and/or for different durations. With embodiments, movement of the seat base 32 between the first and second seat base positions may be relatively subtle and/or may not, on its own, be intended to make the user more alert, but may shift the position of the user, at least to some degree, which may reduce discomfort.


In embodiments, the ECU 50 may operate the vent unit 120 in a cyclical mode for a venting duration, which may include multiple sets of the first vent unit duration, the second vent unit duration, and/or the third vent unit duration. The venting duration may, for example and without limitation, be at least twice as long as the first duration and the second duration combined.


In embodiments, such as generally illustrated in FIGS. 4 and 5, the method 170 may include automatically activating the first bladder assembly 90 (step 180), such as while the ECU 50 operates the vent unit 120 in the first mode and/or the second mode. Activating the first bladder assembly 90 may include periodically/cyclically inflating and/or deflating the first bladder 921, the second bladder 922, the fifth bladder 925, and/or the sixth bladder 926 to massage a lumbar area and/or a shoulder area of the user (see, e.g., plot 154 in FIG. 4). The method 170 may include activating the second bladder assembly 100 (step 182), such as while the ECU 50 operates the vent unit 120 in the first mode and/or the second mode. Activating the second bladder assembly 100 may include periodically/cyclically inflating and/or deflating the bladder 102 of the second bladder assembly 100, such as to reposition the legs and/or hips of the user, at least to some degree, which may reduce fatigue symptoms and/or discomfort (see, e.g., plot 156FIG. 4).


With embodiments, such as generally illustrated in FIGS. 4 and 5, the method 170 may include activating (e.g., automatically) a PEMF coil assembly 130 (step 184), such as while the ECU 50 operates the vent unit 120 in the first mode and/or the second mode. Activating the PEMF coil assembly 130 may include periodically supplying power to the first coil 1321, the second coil 1322, the third coil 1323, the fourth coil 1324, the fifth coil 1325, and/or the sixth coil 1326 (e.g., such as generally shown in plot 158 of FIG. 5) while the first bladder assembly 90 and/or the second bladder assembly 100 are activated. Activating the coils 132N may reduce fatigue symptoms of the user associated with osteo-articular pain and/or inflammation.


In embodiments, the ECU 50 may monitor information of the user to determine if the user exhibits signs and/or symptoms of fatigue and/or discomfort, such as before, during, and/or after operating one or more seat functions (step 186). If the ECU 50 determines that fatigue/symptoms of the user were not sufficiently reduced via operation of one or more seat functions (e.g., the first actuator 80, the second actuator 82, the first bladder assembly 90, the second bladder assembly 100, the vent unit 120, and/or the PEMF coil assembly 130), the ECU 50 may continue to operate and/or cycle operation of one or more seat functions. If the ECU 50 determines that fatigue/symptoms of the user were sufficiently reduced (e.g., the user is fidgeting less, is more alert, etc.), the ECU 50 may deactivate some or all seat functions.


In examples, an ECU 50 may include an electronic controller and/or include an electronic processor, such as a programmable microprocessor and/or microcontroller. In embodiments, an ECU 50 may include, for example, an application specific integrated circuit (ASIC). An ECU 50 may include a central processing unit (CPU), a memory (e.g., a non-transitory computer-readable storage medium), and/or an input/output (I/O) interface. An ECU 50 may be configured to perform various functions, including those described in greater detail herein, with appropriate programming instructions and/or code embodied in software, hardware, and/or other medium. In embodiments, an ECU 50 may include a plurality of controllers. In embodiments, an ECU 50 may be connected to a display, such as a touchscreen display.


Various examples/embodiments are described herein for various apparatuses, systems, and/or methods. Numerous specific details are set forth to provide a thorough understanding of the overall structure, function, manufacture, and use of the examples/embodiments as described in the specification and illustrated in the accompanying drawings. It will be understood by those skilled in the art, however, that the examples/embodiments may be practiced without such specific details. In other instances, well-known operations, components, and elements have not been described in detail so as not to obscure the examples/embodiments described in the specification. Those of ordinary skill in the art will understand that the examples/embodiments described and illustrated herein are non-limiting examples, and thus it can be appreciated that the specific structural and functional details disclosed herein may be representative and do not necessarily limit the scope of the embodiments.


Reference throughout the specification to “examples, “in examples,” “with examples,” “various embodiments,” “with embodiments,” “in embodiments,” or “an embodiment,” or the like, means that a particular feature, structure, or characteristic described in connection with the example/embodiment is included in at least one embodiment. Thus, appearances of the phrases “examples, “in examples,” “with examples,” “in various embodiments,” “with embodiments,” “in embodiments,” or “an embodiment,” or the like, in places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more examples/embodiments. Thus, the particular features, structures, or characteristics illustrated or described in connection with one embodiment/example may be combined, in whole or in part, with the features, structures, functions, and/or characteristics of one or more other embodiments/examples without limitation given that such combination is not illogical or non-functional. Moreover, many modifications may be made to adapt a particular situation or material to the teachings of the present disclosure without departing from the scope thereof.


It should be understood that references to a single element are not necessarily so limited and may include one or more of such element. Any directional references (e.g., plus, minus, upper, lower, upward, downward, left, right, leftward, rightward, top, bottom, above, below, vertical, horizontal, clockwise, and counterclockwise) are only used for identification purposes to aid the reader's understanding of the present disclosure, and do not create limitations, particularly as to the position, orientation, or use of examples/embodiments.


Joinder references (e.g., attached, coupled, connected, and the like) are to be construed broadly and may include intermediate members between a connection of elements and relative movement between elements. As such, joinder references do not necessarily imply that two elements are directly connected/coupled and in fixed relation to each other. The use of “e.g.” in the specification is to be construed broadly and is used to provide non-limiting examples of embodiments of the disclosure, and the disclosure is not limited to such examples. Uses of “and” and “or” are to be construed broadly (e.g., to be treated as “and/or”). For example and without limitation, uses of “and” do not necessarily require all elements or features listed, and uses of “or” are inclusive unless such a construction would be illogical.


While processes, systems, and methods may be described herein in connection with one or more steps in a particular sequence, it should be understood that such methods may be practiced with the steps in a different order, with certain steps performed simultaneously, with additional steps, and/or with certain described steps omitted.


All matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative only and not limiting. Changes in detail or structure may be made without departing from the present disclosure.


It should be understood that an electronic control unit (ECU), a system, and/or a processor as described herein may include a conventional processing apparatus known in the art, which may be capable of executing preprogrammed instructions stored in an associated memory, all performing in accordance with the functionality described herein. To the extent that the methods described herein are embodied in software, the resulting software can be stored in an associated memory and can also constitute means for performing such methods. Such a system or processor may further be of the type having ROM, RAM, RAM and ROM, and/or a combination of non-volatile and volatile memory so that any software may be stored and yet allow storage and processing of dynamically produced data and/or signals.


It should be further understood that an article of manufacture in accordance with this disclosure may include a non-transitory computer-readable storage medium having a computer program encoded thereon for implementing logic and other functionality described herein. The computer program may include code to perform one or more of the methods disclosed herein. Such embodiments may be configured to execute via one or more processors, such as multiple processors that are integrated into a single system or are distributed over and connected together through a communications network, and the communications network may be wired and/or wireless. Code for implementing one or more of the features described in connection with one or more embodiments may, when executed by a processor, cause a plurality of transistors to change from a first state to a second state. A specific pattern of change (e.g., which transistors change state and which transistors do not), may be dictated, at least partially, by the logic and/or code.

Claims
  • 1. A seat assembly, including: a seat including a seat base and a seat back;a sensor;a vent unit disposed at least partially within the seat back; andan electronic control unit (ECU) connected with the sensor and the vent unit;wherein the ECU is configured to determine, via the sensor, if a user of the seat exhibits symptoms of fatigue;the ECU is configured to operate the vent unit in a first mode and a second mode;when the vent unit is in the first mode, the vent unit provides cool air to said user of the seat;when the vent unit is in the second mode, the vent unit provides a lesser amount of cool air and/or air at a higher temperature than the cool air to said user of the seat; andthe ECU is configured to automatically switch the vent unit between the first mode and the second mode to reduce symptoms of fatigue of said user.
  • 2. The seat assembly of claim 1, including a temperature sensor; wherein the ECU is configured to communicate with the temperature sensor to determine an ambient temperature; andthe ECU is configured to control the vent unit such that a cool air temperature of the cool air is lower than the ambient temperature.
  • 3. The seat assembly of claim 2, wherein the ambient temperature is a cabin temperature of a vehicle; and the cool air temperature is at least about 7 degrees Celsius lower than the ambient temperature.
  • 4. The seat assembly of claim 2, wherein the cool air temperature is about 15 degrees Celsius or lower.
  • 5. The seat assembly of claim 1, wherein automatically operating the vent unit includes repeatedly operating the vent unit in the first mode for a first duration and operating the vent unit in the second mode for a second duration to maximize fatigue symptom reduction.
  • 6. The seat assembly of claim 5, wherein the first duration is different than the second duration.
  • 7. The seat assembly of claim 1, including a bladder assembly having one or more bladders disposed in the seat back; wherein the ECU is configured to inflate and deflate the one or more bladders while the vent unit is in the first mode to reduce the fatigue symptoms of said user; andthe sensor includes a pressure sensor at least partially integrated with the bladder assembly.
  • 8. The seat assembly of claim 7, including an additional bladder assembly having one or more additional bladders disposed in the seat base; wherein the ECU is configured to inflate and deflate the one or more additional bladders of the additional bladder assembly while the vent unit is in the first mode to reduce the fatigue symptoms of said user.
  • 9. The seat assembly of claim 1, including a first actuator connected with the seat base and a second actuator connected with the seat back; wherein the ECU is configured to actuate the seat base via the first actuator and actuate the seat back via the second actuator; andwhen the vent unit is in the first mode, the ECU is configured to automatically actuate the seat back from a first seat back position to a second seat back position over a first duration, maintain the second seat back position for a second duration, and return the seat back to the first seat back position after the second duration.
  • 10. The seat assembly of claim 9, wherein a first angle between the first seat back position and the second seat back position is about 1.5 degrees.
  • 11. The seat assembly of claim 10, wherein the ECU is configured to actuate the seat base from a first seat base position to a second seat base position during the first duration; a second angle between the first seat base position and the second seat base position is about 1 degree; andthe first duration is longer than the second duration.
  • 12. The seat assembly of claim 11, wherein the first duration is about four minutes and the second duration is about six minutes.
  • 13. The seat assembly of claim 11, wherein symptoms of fatigue include one or more of user movements relative to the seat, reduced or irregular heart rate, reduced or irregular heart rate variability, and/or reduced or irregular blood pressure.
  • 14. The seat assembly of claim 1, including a pulsed electromagnetic field (PEMF) coil assembly including at least one coil; wherein the ECU is configured to activate the at least one coil while the vent unit is in the first mode to reduce the fatigue symptoms of said user.
  • 15. A seat assembly, including: a seat including a seat base, a seat back, and a headrest;a bladder assembly disposed at least partially in the seat;a biomedical sensor configured to sense biomedical information of a user of the seat, the biomedical sensor at least partially integrated with the bladder assembly;an actuator assembly configured to control a position of the seat base and/or the seat back;a vent unit disposed at least partially within the seat back and including a portion disposed proximate the headrest;a PEMF coil assembly disposed at least partially in the seat back; andan ECU configured to control the actuator assembly, the bladder assembly, the vent unit, and the PEMF coil assembly;wherein the ECU is configured to determine if the user of the seat exhibits symptoms of fatigue via the biomedical sensor;the ECU is configured to automatically operate the vent unit in a first mode and a second mode in an alternating configuration to reduce the fatigue symptoms of said user;when the vent unit is in the first mode, the vent unit provides cool air to an area proximate a neck of said user;when the vent unit is in the second mode, the vent unit provides a lesser amount of cool air and/or provides air at a higher temperature than the cool air; andthe ECU is configured to automatically activate the actuator assembly, the bladder assembly, and the PEMF coil assembly when the vent unit is in the first mode to reduce the fatigue symptoms of said user.
  • 16. A method of operating a seat assembly including a seat, a biomedical sensor, a vent unit, and an ECU connected with the biomedical sensor and the vent unit, the method including: sensing, via the biomedical sensor, if a user of the seat exhibits symptoms of fatigue; andautomatically operating the vent unit in a first mode for a first duration and in a second mode for a second duration to reduce symptoms of fatigue of said user;wherein when the vent unit is in the first mode, the vent unit supplies cool air to said user; andwhen the vent unit is in the second mode, the vent unit provides a lesser amount of cool air and/or provides air at a higher temperature than the cool air.
  • 17. The method of claim 16, wherein automatically operating the vent unit includes alternating between the first mode and the second mode for a venting duration to maximize an effectiveness of the vent unit for reducing symptoms of fatigue.
  • 18. The method of claim 17, wherein the first duration is less than the second duration; and the venting duration is at least twice as long as the first duration and the second duration combined.
  • 19. The method of claim 16, wherein the cool air includes a temperate that is at least about 7 degrees cooler than a cabin temperature and is about 15 degrees Celsius or lower.
  • 20. The method of claim 16, including automatically operating an actuator assembly, a bladder assembly, and a coil assembly to reduce the symptoms of fatigue of the user while automatically operating the vent unit.
US Referenced Citations (153)
Number Name Date Kind
5769490 Falzon Jun 1998 A
6056360 Schneider May 2000 A
6079485 Esaki et al. Jun 2000 A
6088642 Finkelstein et al. Jul 2000 A
6088643 Long et al. Jul 2000 A
6098000 Long et al. Aug 2000 A
6179378 Baumgartner et al. Jan 2001 B1
6345839 Kuboki et al. Feb 2002 B1
6353207 Burt Mar 2002 B1
6506153 Littek et al. Jan 2003 B1
6559422 Burt May 2003 B2
6682494 Sleichter, III et al. Jan 2004 B1
6908152 McMillen Jun 2005 B2
7011369 Massara et al. Mar 2006 B2
7083232 Frank Aug 2006 B2
7083233 Massara et al. Aug 2006 B2
7152920 Sugiyama et al. Dec 2006 B2
7201446 Massara et al. Apr 2007 B2
7219923 Fujita et al. May 2007 B2
7267652 Coyle et al. Sep 2007 B2
7303231 Frank Dec 2007 B2
7314451 Halperin et al. Jan 2008 B2
7417536 Lakshmanan et al. Aug 2008 B2
7688582 Fukazu et al. Mar 2010 B2
7731279 Asada et al. Jun 2010 B2
7808395 Raisanen et al. Oct 2010 B2
7828050 Esaki Nov 2010 B2
7862119 Schafer et al. Jan 2011 B2
7866755 Okano Jan 2011 B2
7900736 Breed Mar 2011 B2
7967379 Walters et al. Jun 2011 B2
7967381 Sugiyama Jun 2011 B2
8341786 Oexman et al. Jan 2013 B2
8444558 Young et al. May 2013 B2
8616654 Zenk et al. Dec 2013 B2
8618451 Kunisada Dec 2013 B2
8706204 Seo et al. Apr 2014 B2
8710784 Meyer et al. Apr 2014 B2
8725311 Breed May 2014 B1
8794707 Bocsanyi et al. Aug 2014 B2
8827372 Yoon Sep 2014 B2
8958955 Hotary et al. Feb 2015 B2
8971839 Hong Mar 2015 B2
8979191 Friderich et al. Mar 2015 B2
8989697 Leung et al. Mar 2015 B2
9147192 Dawson et al. Sep 2015 B2
9237242 Basir Jan 2016 B2
9272647 Gawade Mar 2016 B2
9272689 Fung et al. Mar 2016 B2
9277385 Iwamoto Mar 2016 B2
9504416 Young et al. Nov 2016 B2
9815385 Lippman et al. Nov 2017 B2
9848814 Benson et al. Dec 2017 B2
9883821 Muehlsteff Feb 2018 B2
9978283 Jedrzejewski et al. May 2018 B2
9980680 Matsumoto May 2018 B2
10034631 Gallagher et al. Jul 2018 B1
10210409 Migneco et al. Feb 2019 B1
10213147 Gallagher et al. Feb 2019 B2
10308258 Fung et al. Jun 2019 B2
10328823 O'Bannon et al. Jun 2019 B2
10358065 McMillen et al. Jul 2019 B2
10369074 Oberg et al. Aug 2019 B2
10379535 Migneco et al. Aug 2019 B2
10391900 Zhao Aug 2019 B2
10470968 Saren et al. Nov 2019 B2
10471868 Wheeler Nov 2019 B2
10492979 Norman et al. Dec 2019 B2
10556532 Gallagher et al. Feb 2020 B2
10569668 Migneco et al. Feb 2020 B2
10576855 Dorfler et al. Mar 2020 B2
10640010 Yetukuri et al. May 2020 B2
10709386 Gallagher et al. Jul 2020 B2
10807439 Migneco et al. Oct 2020 B2
10898708 Franco-Obregon Jan 2021 B2
20030039298 Eriksson et al. Feb 2003 A1
20030075959 Xue et al. Apr 2003 A1
20030209893 Breed et al. Nov 2003 A1
20040119599 Stevenson et al. Jun 2004 A1
20040129478 Breed et al. Jul 2004 A1
20060244289 Bedro Nov 2006 A1
20070118054 Pinhas et al. May 2007 A1
20080161989 Breed Jul 2008 A1
20080216567 Breed Sep 2008 A1
20080255731 Mita et al. Oct 2008 A1
20080267460 Aoki et al. Oct 2008 A1
20080288406 Seguin et al. Nov 2008 A1
20090008970 Flory et al. Jan 2009 A1
20090030578 Periot et al. Jan 2009 A1
20100087748 Tobola et al. Apr 2010 A1
20110015468 Aarts et al. Jan 2011 A1
20120080911 Brykalski Apr 2012 A1
20120086249 Hotary et al. Apr 2012 A1
20120089299 Breed Apr 2012 A1
20120116149 Pilla May 2012 A1
20130090816 Huber Apr 2013 A1
20130127210 Jung et al. May 2013 A1
20130251216 Smowton et al. Sep 2013 A1
20140070943 Breed Mar 2014 A1
20140132042 Midderhoff et al. May 2014 A1
20140207333 Vandivier et al. Jul 2014 A1
20140319895 Lange-Mao et al. Oct 2014 A1
20140361871 Silva et al. Dec 2014 A1
20140375089 Qureshi et al. Dec 2014 A1
20150048658 Gawade Feb 2015 A1
20150084985 Baudu Mar 2015 A1
20150266405 Fitzpatrick et al. Sep 2015 A1
20150313475 Benson et al. Nov 2015 A1
20150351692 Pereny et al. Dec 2015 A1
20150352979 O'Bannon et al. Dec 2015 A1
20150352990 Zouzal et al. Dec 2015 A1
20150375653 Josefsson et al. Dec 2015 A1
20160001781 Fung et al. Jan 2016 A1
20160003882 Loftus Jan 2016 A1
20160143803 Portales May 2016 A1
20160176409 Kirsch et al. Jun 2016 A1
20160250956 Seiting et al. Sep 2016 A1
20160278709 Ridao Granado et al. Sep 2016 A1
20170043681 Seiller et al. Feb 2017 A1
20170086588 Patrick et al. Mar 2017 A1
20170225591 Tobata et al. Aug 2017 A1
20170274906 Hassan et al. Sep 2017 A1
20170349061 Benson et al. Dec 2017 A1
20170361748 Meachum et al. Dec 2017 A1
20180008507 Saren et al. Jan 2018 A1
20180009343 Saren et al. Jan 2018 A1
20180065642 Frye et al. Mar 2018 A1
20180110960 Youngblood Apr 2018 A1
20180178692 Zhao Jun 2018 A1
20180178808 Zhao et al. Jun 2018 A1
20180215293 Gandhi et al. Aug 2018 A1
20180325264 Gallagher et al. Nov 2018 A1
20180345833 Gallagher et al. Dec 2018 A1
20190053761 Young et al. Feb 2019 A1
20190054796 Thomas Feb 2019 A1
20190126036 Franco-Obregon et al. May 2019 A1
20190133511 Migneco et al. May 2019 A1
20190168771 Migneco et al. Jun 2019 A1
20190193591 Migneco et al. Jun 2019 A1
20190239815 Gallagher et al. Aug 2019 A1
20190275860 Migneco et al. Sep 2019 A1
20190332902 Gallagher et al. Oct 2019 A1
20190337412 Zouzal et al. Nov 2019 A1
20190337431 McMillen et al. Nov 2019 A1
20190344043 Migneco et al. Nov 2019 A1
20200035237 Kim et al. Jan 2020 A1
20200113344 Youngblood Apr 2020 A1
20200170576 Lerner Jun 2020 A1
20200188211 Ellermann Jun 2020 A1
20200231428 Migneco et al. Jul 2020 A1
20200253381 Dorfler et al. Aug 2020 A1
20200324675 Yamamoto et al. Oct 2020 A1
20210016686 Yetukuri et al. Jan 2021 A1
Foreign Referenced Citations (56)
Number Date Country
2855822 Jan 2007 CN
203186154 Sep 2013 CN
104252615 Dec 2014 CN
205468657 Aug 2016 CN
10027686 Jan 2002 DE
10063478 Jul 2002 DE
102004010626 Jun 2005 DE
102004013674 Oct 2005 DE
102006029871 Jan 2008 DE
102008029339 Jan 2009 DE
102009008421 Oct 2009 DE
102009035566 Feb 2010 DE
102009031331 Aug 2010 DE
102009033041 Jan 2011 DE
102010021332 Jan 2011 DE
102010049152 Nov 2011 DE
102011012431 Nov 2011 DE
102011016073 Dec 2011 DE
102011017238 Dec 2011 DE
102011102021 Nov 2012 DE
102011113100 Mar 2013 DE
102011116194 Apr 2013 DE
102012201430 Apr 2013 DE
102012216869 Mar 2014 DE
202015104103 Aug 2015 DE
102014002942 Sep 2015 DE
102015011460 Mar 2016 DE
102015011461 Mar 2016 DE
102017110812 Jan 2018 DE
102016011481 Mar 2018 DE
202017103162 May 2018 DE
102018000765 Aug 2019 DE
102018001230 Aug 2019 DE
202019100400 Jan 2020 DE
202019100710 Feb 2020 DE
102018007921 Apr 2020 DE
202019102879 May 2020 DE
202019105369 May 2020 DE
102019008724 Aug 2020 DE
1077154 Feb 2001 EP
1749477 Feb 2007 EP
1932715 Jun 2008 EP
2149475 Feb 2010 EP
2205460 Mar 2016 EP
2988654 Oct 2013 FR
2512136 Sep 2014 GB
2001269380 Oct 2001 JP
2005137896 Jun 2005 JP
2005237456 Sep 2005 JP
2006014756 Jan 2006 JP
3857869 Dec 2006 JP
2009172145 Aug 2009 JP
2012196253 Oct 2012 JP
2013163405 Aug 2013 JP
2019131049 Aug 2019 JP
2012039368 Mar 2012 WO
Non-Patent Literature Citations (5)
Entry
Co-pending U.S. Appl. No. 16/821,128, filed Mar. 17, 2020.
Co-pending U.S. Appl. No. 15/930,777, filed May 13, 2020.
Co-pending U.S. Appl. No. 15/930,802, filed May 13, 2020.
Co-pending U.S. Appl. No. 15/930,865, filed May 13, 2020.
Co-pending U.S. Appl. No. 17/109,652, filed Dec. 2, 2020.